关于伪原生的生物活动和临床应用的研究进展
Jie Li1,2, Senling Feng3, Zhenya Du1
1Faculty of Chinese Medicine and State Key Laboratory of Mechanism and Quality of Chinese, Macau University of Science and Technology, Macau 999078, China.
Current issues in molecular biology
|November 26, 2025
概括
伪益生素 (PPD) 是来自迪奥斯科雷亚植物的类固醇素,具有抗癌和抗炎作用. 需要进一步的研究来提高其生物可用性,以提高药物输送和临床使用.
科学领域:
- 药理学 药理学是指药理学的学科.
- 自然产品 化学 化学
- 药物开发 药物开发
背景情况:
- 伪原氨酸 (PPD) 是一种从迪奥斯科里亚植物中提取的类固醇氨酸.
- PPD表现出显著的生物活动,并具有相当大的治疗前景.
研究的目的:
- 审查PPD的药理性质和临床应用.
- 确定PPD研究和开发的挑战和未来方向.
主要方法:
- 使用关键字"Dioscorea"和"pseudoprotodioscin"进行文献搜索.
- 包括来自主要科学数据库 (PubMed,科学网等) 的研究. 和相关的网站.
主要成果:
- 在PPD中表现出抗癌,抗炎,肝保护和心脏保护作用.
- 药物动力学研究显示,大鼠的快速分泌和低生物利用率 (5.7%),需要先进的药物输送系统,如纳米颗粒.
- 含有PPD的中国专利药物显示在治疗相关疾病方面具有潜力.
结论:
- PPD及其相关的中国专利药物具有重要的治疗潜力.
- 优化PPD的药理动力学概况对于未来的临床开发至关重要.
- 对PPD的作用机制和完整的药理范围进行进一步的研究是有必要的.
更多相关视频
11:00Methods to Inhibit Bacterial Pyomelanin Production and Determine the Corresponding Increase in Sensitivity to Oxidative Stress
Published on: August 31, 2015
8.7K
06:39Author Spotlight: Exploring Photodynamic Therapy with Curcumin in a Murine Model for Oral Candidiasis
Published on: October 27, 2023
1.4K
相关概念视频
Preclinical Development: Overview
5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Prodrugs
3.8K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
3.8K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
430
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
430
